// you’re reading...

General Biotechnology

Why Merck Missed the Mark

By Yali ⋅ October 24, 2003 ⋅ Email This Post Email This Post ⋅ Print This Post Print This Post ⋅ Post a comment

Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold

Print This Post

Discussion

No comments for “Why Merck Missed the Mark”

Post a comment

Building Biotechnology - Starting, Managing, and Understanding Biotechnology Companies   The Business of Biotechnology - Profit From the Growing Influence of Biotechnology
Best Practices in Biotechnology Business Development Best Practices in Biotechnology Education
Journal of Commercial Biotechnology 
DrugPatentWatch.com